VitaLonga

Animal study · Supplements / medicine · 20 Nov 2026

In mice, imeglimin lined up with less islet injury after transplant; human islets have not been tested

Source: Kyoto University

What the research found

A 20 November 2026 research note from Kyoto University, written in Japanese, reports mouse work by Muhammad Fauzi, Takaaki Murakami, Daisuke Yabe, and colleagues. Imeglimin, a medicine already used for type 2 diabetes, limited low-oxygen injury in mouse islets and lined up with better early engraftment and glucose control after islet transplant in a mouse model of type 1 diabetes. In the islet experiments, mitochondrial function held up and reactive oxygen species rose less. A receptor-targeted scan, indium-111 exendin-4 SPECT/CT, showed more beta-cell signal at day 14. The group says that scan is a tool they hope to use in care, and the figure in the release is a diagram, not a measured image. The paper appeared online in Diabetes on 18 November 2026 and was picked as a Paper of the Month. The authors say the next check has to be human islets. This is not a study of imeglimin for a longer life, and it is not a reason to start, stop, or swap a prescribed diabetes medicine. DOI 10.2337/db26-0360. Not medical advice.

Evidence level: Animal study. Results in animals or cells often don't carry over to people.

Read the original at Kyoto University

More supplements / medicine news